Literature DB >> 14594569

Management of hypertension emergencies.

William J Elliott1.   

Abstract

Although they have become less common, hypertensive emergencies occur with an incidence of approximately 1 to 2/100,000 people per year. Our knowledge about this problem, its pathophysiology, risk factors, and appropriate treatment options has expanded during the past decade. A hypertensive emergency can be declared when an elevated blood pressure is associated with acute target-organ damage. Rapid evaluation and treatment (typically with an intravenously administered agent) should be instituted, usually in an intensive care unit setting, and the patient should be observed carefully during acute blood-pressure lowering. When properly treated, the prognosis for these patients is not nearly as dismal as it was more than 60 years ago, and the initial level of function of target organs (brain, heart, kidneys) is more indicative of an emergency than the actual level of blood pressure. Therapeutic options include the time-tested sodium nitroprusside (which has toxic metabolic products and is contraindicated in pregnancy, tobacco amblyopia, and Leber's optic atrophy); fenoldopam mesylate; and nicardipine. When properly treated, "malignant hypertension" need be considered malignant no longer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594569     DOI: 10.1007/s11906-003-0056-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  47 in total

Review 1.  Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.

Authors:  M B Murphy; C Murray; G D Shorten
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

2.  Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor.

Authors:  H Suzuki; K Asano; M Eiro; M Kuriki; S Hashimoto; T Katoh; T Watanabe; K Watanabe
Journal:  QJM       Date:  2002-02

3.  Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension.

Authors:  J Kato; K Kitamura; E Matsui; M Tanaka; Y Ishizaka; T Kita; K Kangawa; T Eto
Journal:  Hypertens Res       Date:  1999-03       Impact factor: 3.872

4.  Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception.

Authors:  G Y Lip; M Beevers; D G Beevers
Journal:  QJM       Date:  1997-09

5.  Lack of difference between malignant and accelerated hypertension.

Authors:  M E Ahmed; J M Walker; D G Beevers; M Beevers
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

6.  Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration.

Authors:  K Oka; K Hayashi; T Nakazato; T Suzawa; K Fujiwara; T Saruta
Journal:  Intern Med       Date:  1997-10       Impact factor: 1.271

7.  Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.

Authors:  N H Shusterman; W J Elliott; W B White
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

8.  Two cases of malignant hypertension with reversible diffuse leukoencephalopathy exhibiting a reversible nocturnal blood pressure "riser" pattern.

Authors:  Kazuo Eguchi; Kentaro Kasahara; Akinori Nagashima; Tadashi Mor; Takanobu Nii; Kazuo Ibaraki; Kazuomi Kario; Kazuyuki Shimada
Journal:  Hypertens Res       Date:  2002-05       Impact factor: 3.872

9.  Recovery in malignant hypertension presenting as acute renal failure.

Authors:  C G Isles; A McLay; J M Jones
Journal:  Q J Med       Date:  1984

10.  Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.

Authors:  J R Piltz; R A Stone; S Boike; D E Everitt; N H Shusterman; P Audet; N Zariffa; D K Jorkasky
Journal:  J Ocul Pharmacol Ther       Date:  1998-06       Impact factor: 2.671

View more
  2 in total

1.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

Review 2.  Clinical features and management of selected hypertensive emergencies.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.